Tongjitang Resumes Production After Earthquake Damage

- Reopens Xiuwen Facility-
SHENZHEN, China--(Business Wire)--
Tongjitang Chinese Medicines Company (NYSE: TCM), a leading
specialty pharmaceutical company focusing on the development,
manufacturing, marketing and selling of modernized traditional Chinese
medicine in China, today announced that production at its Xiuwen
facility has resumed, one week after an earthquake devastated Central
China.

Xiaochun Wang, Tongjitang's Chief Executive Officer and Chairman
of its Board of Directors, stated, "We are delighted to announce that
production has recommenced, but remember those still affected. Our
thoughts remain with those suffering as a result of this terrible
tragedy."

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating
subsidiaries Tongjitang Pharmaceutical, Guizhou LLF Pharmaceutical,
Tongjitang Distribution, Tongjitang Chain Stores, and Tongjitang
Planting, is a vertically integrated and profitable specialty
pharmaceutical company focusing on the development, manufacturing,
marketing and selling of modernized traditional Chinese medicine in
China. Tongjitang's principal executive offices are located in
Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading
traditional Chinese medicine for the treatment of osteoporosis in
China as measured by sales in Renminbi amounts. In addition to
Xianling Gubao, the company manufactures and markets 10 other
modernized traditional Chinese medicine products and 37 western
medicines. Visit www.tongjitang.com for more information.

Safe Harbor Statement

This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Although the Company believes that the
expectations reflected in such forward-looking statements are based on
reasonable assumptions, such statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, they cannot assure you that their expectations will turn
out to be correct, and investors are cautioned that actual results may
differ materially from those described in the forward -looking
statements in this press release. A number of factors could cause
actual results to differ materially from those contained in any
forward-looking statement, including but not limited to the following:
our growth strategy; our future business development, results of
operations and financial condition; our heavy dependence on the
success of Xianling Gubao; our ability to market Xianling Gubao to
hospitals and to retail pharmacies; the retail prices of our principal
products' being subject to price control by the government authorities
in China; our products' inclusion in national and provincial medical
catalogs of the National Medical Insurance Program in China; our
ability to obtain approval from the State Food and Drug Administration
in China to convert a provisional national production standard of our
principal products to a national final production standard; our
ability to continue having the exclusive production rights for our
products; our ability to further improve our barrenwort extraction
efficiency; our ability to obtain manufacturing or marketing approval
for our future products; our dependence on a limited number of
distributors for a significant portion of our net revenues; our
ability to protect our intellectual property rights and defend
infringement or misappropriation claims by third parties; intense
competition in the pharmaceutical market in China; the supply of
quality medicinal raw materials; and uncertainties with respect to the
legal system in China. Further information regarding these and other
risks is and will be included in our registration statement on Form
F-1 and other documents filed and to be filed with the U.S. Securities
and Exchange Commission. The Company does not undertake any obligation
to update any forward-looking statement, except as required under
applicable law. All information provided in this press release is as
of the date of this press release, and the Company undertakes no duty
to update such information, except as required under applicable law.

Integrated Corporate Relations, Inc.
Investor Relations:
Ashley Ammon MacFarlane and Christine Duan
203-682-8200

Copyright Business Wire 2008